This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.


June 19, 2017
Chudgar and colleagues evaluated clinicopathologic variables and characteristics of treatment for 539 patients who had undergone pulmonary metastasectomy for soft-tissue sarcoma at the Memorial Sloan Kettering Cancer Center.
April 23, 2017
Check out this focused issue by JOVS with partecipation of major experts from the globe. Is subxiphoid approach the future for lung resections? 
March 5, 2017
The authors report the use of ECMO in 8 pts who suffered ARDS after pneumonectomy.  Predicted mortality was 80% prior to ECMO institution.  ECMO was weaned in 7 pts and overall hospital survival was 50%.  
September 26, 2016
The authors present the case of a complex mediastinal bronchogenic cyst that was excised through a right VATS approach.
July 24, 2016
The authors, using 2 groups of patients, 32 ECMO and 53 non-ECMO, both with a diagnosis of ARDS, describe the two groups' severity of illness, medication regimen and use or nonuse of ECMO therapy.
May 5, 2016
The goal of this multicenter survey was to determine the psychological and social impact of incidental pulmonary nodule detection.
April 6, 2016
Doug Mathisen reflects on his three decades of practice in a new interview that was filmed at the 2016 SCTS Annual Meeting in Birmingham, United Kingdom.
March 7, 2016
Using data from the National Cancer Data Base, the surgical and oncologic efficacy of minimally invasive (VATS, robotic) lobectomy were compared to open lobectomy.  Groups were created for comparison using propensity score matching techniques.  VATS compared to open was associated with shorter LOS, higher readmission rates, and slightly better 2-year
January 30, 2016
Readmission after lung resection is associated with increased costs and is used as a benchmark for quality.  Outcomes of more than 22,000 lobectomies were evaluated for factors associated with readmission.  30- and 90-day readmission rates were 11.5% and 19.8%.  Causes for readmission were pulmonary (24%), cardiovascular (16%), and surgical/procedura
August 26, 2015
Investigators from Stanford developed a nine-gene expression predictor for survival outcome in early-stage nonsquamous NSCLC. They developed and validated a quantitative real-time polymerase chain reaction assay easily applicable to routinely obtained paraffin-embedded tumor specimens.